QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
NASDAQ:EQRX

EQRx News Headlines

$4.20
-0.09 (-2.10%)
(As of 01/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$4.16
▼
$4.60
50-Day Range
N/A
52-Week Range
$3.97
▼
$11.10
Volume
881,535 shs
Average Volume
948,246 shs
Market Capitalization
$2.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Get EQRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for EQRX and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

EQRx Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EQRX
News Sentiment
▼
0.32

0.29
▲
Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EQRX Articles
This Week
▼
3

6
▲
EQRX Articles
Average Week



EQRx (NASDAQ:EQRX) News Headlines Today

SourceHeadline
MarketBeat logoEQRx (NASDAQ:EQRX) Shares Up 2.4%
americanbankingnews.com - January 25 at 11:48 AM
msn.com logoCramer Gives His Opinion On ADT, Occidental Petroleum And More
msn.com - January 25 at 7:59 AM
MarketBeat logoEQRx (NASDAQ:EQRX) Shares Gap Up to $4.43
americanbankingnews.com - January 24 at 12:50 PM
MarketBeat logoEQRx (NASDAQ:EQRX) Shares Gap Down to $5.43
americanbankingnews.com - January 20 at 11:33 AM
finance.yahoo.com logoEQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings
finance.yahoo.com - January 19 at 6:25 PM
MarketBeat logoEQRx (NASDAQ:EQRX) Sets New 1-Year Low at $5.51
americanbankingnews.com - January 19 at 3:44 PM
seekingalpha.com logoCStone-EQRx's sugemalimab improves survival of lung cancer patients in phase 3 trial
seekingalpha.com - January 19 at 1:25 PM
finance.yahoo.com logoSugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
finance.yahoo.com - January 19 at 8:24 AM
nasdaq.com logoEQRx : Phase 3 Study On Sugemalimab Shows Overall Survival Benefit In Non-small Cell Lung Cancer
nasdaq.com - January 19 at 8:24 AM
msn.com logoInvestors aren't buying EQRx's pitch for 'radically lower' drug prices. The CEO of the $3 billion startup tells us why she's doubling down despite a stock drop.
msn.com - January 19 at 8:24 AM
finance.yahoo.com logoEQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer
finance.yahoo.com - January 19 at 8:24 AM
finance.yahoo.com logoSugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
finance.yahoo.com - January 19 at 8:24 AM
MarketBeat logoEQRx (NASDAQ:EQRX) Shares Gap Up to $6.45
americanbankingnews.com - January 18 at 12:48 PM
MarketBeat logoEQRx (NASDAQ:EQRX) Trading Down 8.1%
americanbankingnews.com - January 14 at 3:44 PM
MarketBeat logoEQRx (NASDAQ:EQRX) Shares Gap Down to $7.20
americanbankingnews.com - January 13 at 11:56 AM
MarketBeat logoEQRx (NASDAQ:EQRX) Trading Up 12%
americanbankingnews.com - January 11 at 1:48 PM
MarketBeat logoEQRx (NASDAQ:EQRX) Shares Gap Up to $6.46
americanbankingnews.com - January 10 at 11:38 AM
MarketBeat logoEQRx (NASDAQ:EQRX) Trading Down 6.4%
americanbankingnews.com - January 7 at 4:14 PM
Get EQRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for EQRX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.